Epic Sciences Gets Phase II SBIR Grant for Lung Cancer Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – Epic Sciences today said that it has received a Phase II Small Business Innovation Research award from the National Cancer Institute and the National Institutes of Health to develop a lung cancer assay.

The test would identify and characterize circulating tumor cells in lung cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.